Wall Street analysts forecast that Vitamin Shoppe Inc (NYSE:VSI) will report earnings per share of ($0.24) for the current quarter, according to Zacks. Two analysts have made estimates for Vitamin Shoppe’s earnings. The highest EPS estimate is ($0.04) and the lowest is ($0.35). Vitamin Shoppe reported earnings per share of $0.36 in the same quarter last year, which suggests a negative year over year growth rate of 166.7%. The company is expected to announce its next earnings report on Wednesday, March 7th.

According to Zacks, analysts expect that Vitamin Shoppe will report full-year earnings of $0.34 per share for the current year, with EPS estimates ranging from $0.22 to $0.52. For the next fiscal year, analysts expect that the firm will post earnings of $0.29 per share, with EPS estimates ranging from $0.20 to $0.52. Zacks’ EPS averages are an average based on a survey of analysts that cover Vitamin Shoppe.

Vitamin Shoppe (NYSE:VSI) last posted its quarterly earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.17 by ($0.20). The firm had revenue of $288.20 million during the quarter, compared to the consensus estimate of $297.61 million. Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. The business’s revenue for the quarter was down 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.50 earnings per share.

A number of research firms have weighed in on VSI. ValuEngine lowered shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Barclays dropped their price target on shares of Vitamin Shoppe from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Thursday, November 9th. Morgan Stanley dropped their price target on shares of Vitamin Shoppe from $7.50 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, November 9th. Finally, Zacks Investment Research lowered shares of Vitamin Shoppe from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Four research analysts have rated the stock with a sell rating and five have assigned a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $5.00.

In related news, major shareholder Vintage Capital Management Llc bought 133,804 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was purchased at an average price of $4.28 per share, for a total transaction of $572,681.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have purchased 694,839 shares of company stock valued at $3,214,809. 1.07% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of VSI. Russell Investments Group Ltd. boosted its position in shares of Vitamin Shoppe by 16.7% during the second quarter. Russell Investments Group Ltd. now owns 26,788 shares of the specialty retailer’s stock worth $312,000 after acquiring an additional 3,839 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Vitamin Shoppe by 34.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 262,123 shares of the specialty retailer’s stock worth $3,054,000 after acquiring an additional 67,362 shares during the last quarter. Arizona State Retirement System boosted its position in shares of Vitamin Shoppe by 0.8% during the second quarter. Arizona State Retirement System now owns 12,460 shares of the specialty retailer’s stock worth $145,000 after acquiring an additional 100 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Vitamin Shoppe by 9.3% during the second quarter. Legal & General Group Plc now owns 44,555 shares of the specialty retailer’s stock worth $518,000 after acquiring an additional 3,789 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in shares of Vitamin Shoppe by 2.1% during the second quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the specialty retailer’s stock worth $108,000 after acquiring an additional 192 shares during the last quarter. Hedge funds and other institutional investors own 90.35% of the company’s stock.

Vitamin Shoppe (NYSE VSI) traded down $0.05 on Monday, hitting $5.25. 1,317,900 shares of the company’s stock were exchanged, compared to its average volume of 613,118. The company has a market capitalization of $125.88, a price-to-earnings ratio of -0.50 and a beta of 0.68. Vitamin Shoppe has a fifty-two week low of $2.95 and a fifty-two week high of $23.85. The company has a current ratio of 2.07, a quick ratio of 0.32 and a debt-to-equity ratio of 0.59.

ILLEGAL ACTIVITY WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/01/08/0-24-eps-expected-for-vitamin-shoppe-inc-vsi-this-quarter.html.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Get a free copy of the Zacks research report on Vitamin Shoppe (VSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.